Trending Topic

virus closeup, contagious pathogen. Monkey pox virus closeup, contagious pathogen, infectious zoonotic disease
7 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

A double-stranded DNA virus of the Orthopoxvirus family, mpox (formerly monkeypox), continues to infect people daily, following the 2022 global outbreak.1 Two clades (clade 1 and clade 2) have been identified, with the 2022 outbreak caused by a subclade of clade 2, referred to as clade 2b.2 Comparatively, clade 1 leads to a more severe disease state and greater […]

Search Results

Showing Results for respiratory syncytial virus

Speciality Filter

Select Specialty or Clinical Area

Clear All
Update Filters
Close Popup
Mark CompleteCompleted
BookmarkBookmarked

Dr. Jon Salmanton-García discusses unmet needs in preventing and treating respiratory infections in haematology patients, highlighting real-world data insights and the urgent need for targeted vaccines and antivirals.

Mark CompleteCompleted
BookmarkBookmarked

Respiratory syncytial virus (RSV) is often of increased concern in the autumn and winter months, especially for women who are pregnant, or those with newborns.1 Worldwide, RSV is the second leading cause of death (second to malaria) in children during ...

Developed by Touch
Coverage from: CROI Coverage

HIV vaccine development, emphasizing HIV, RSV, and coronavirus COVID-19 research is discussed by Prof. Barney Graham. This information is crucial for immunologists, virologists, and those in vaccine research. Learn from cross-disciplinary strategies. You, as healthcare professionals in these fields, need to grasp these insights for innovation. HIV, RSV, and coronavirus studies offer valuable lessons. Keep up with the latest in vaccine technology.

Mark CompleteCompleted
BookmarkBookmarked

Initial attempts to develop a HIV vaccine focused on creating a vaccine that would generate neutralizing antibodies against the virus, using portions of the HIV envelope from prototype laboratory isolates. The initial attempts using monomeric envelope proteins of largely laboratory ...

Coverage from: ID Week Coverage

Respiratory syncytial virus (RSV) present a significant disease burden in children and older adults. Currently, there are no approved vaccines against RSV. In this touchINFECTIOUS DISEASES interview, we met with Prof. Michael Ison (Northwestern University Feinberg School of Medicine, Chicago, ...

Developed by Touch
Coverage from: ID Week Coverage

Respiratory syncytial virus (RSV) presents a significant disease burden in older adults, with no approved vaccines to protect against RSV. In this touchINFECTIOUS DISEASES interview, we met with Prof. Michael Ison (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) ...

Developed by Touch
Coverage from: ID Week Coverage

In this touchINFECTIOUS DISEASES interview, we met with Prof. Michael Ison (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) to discuss his highlights from IDWeek 2022. He highlights vaccine development applied outside of COVID-19, and transformational RSV vaccines, antivirals, antifungals ...

Developed by Touch

Following the recent results from the pivotal Phase III MELODY and Phase IIb trials of nirsevimab in the treatment of respiratory syncytial virus, we were delighted to speak with Dr. Joseph Domachowske (Upstate University Hospital, Syracuse, NY, USA) to discuss ...

Developed by Touch

Following the recent phase III and phase IIb data for nirsevimab in the treatment of respiratory syncytial virus (RSV), we were delighted to speak with Dr. Joseph Domachowske (Upstate University Hospital, Syracuse, NY, USA) to discuss the unmet needs in ...

Close Popup